A drug that outperforms placebo in helping people to lose weight is one of a growing number of next-generation obesity drugs being produced in ... the drug lost up to 13.8 kilograms over 48 weeks of ...

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...

Objective This report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological ...

Slashing health care support for low-income Californians isn’t just a budget decision, it is a public health crisis in the ...

As rates of MASLD, which is linked to obesity and diabetes, rise, new therapies have emerged, but better diagnostic and ...

For instance, survivors with cancers related to obesity often face higher risks for cancer recurrence and death—not just from ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

The American College of Cardiology has issued new guidelines recommending weight management medications as first-line treatments for eligible patients. This contrasts with prior guidelines that ...